



Kala Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

May 30, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--May 30, 2019-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Jefferies 2019 Healthcare Conference in New York, NY. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Thursday, June 6, 2019 at 2:30 p.m. ET.

To access a live webcast and subsequent archived recording of the presentation, please visit "Events" in the "Investors" section of the Kala website at <http://kalarx.com>.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYS® for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a target action date under the Prescription Drug User Fee Act (PDUFA) has been set by the United States Food and Drug Administration (FDA) for August 15, 2019.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190530005030/en/>

Source: Kala Pharmaceuticals, Inc.

Investor:

Michael Schaffzin, 212-362-1200
michael.schaffzin@sternir.com

or

Media:

Kari Watson, 781-235-3060
kwatson@machbiocom.com